Pioglitazone
- Generic Name
- Pioglitazone
- Brand Names
- Actoplus Met, Actos, Duetact, Incresync, Oseni, Tandemact, Pioglitazone Accord, Pioglitazone Actavis
- Drug Type
- Small Molecule
- Chemical Formula
- C19H20N2O3S
- CAS Number
- 111025-46-8
- Unique Ingredient Identifier
- X4OV71U42S
- Background
Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus. It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert in vivo with little consequence. The thiazolidinedione class of medicatio...
- Indication
Pioglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is also available in combination with metformin, glimepiride, or alogliptin for the same indication.
- Associated Conditions
- Diabetes, Diabetic Neuropathies, Type 2 Diabetes Mellitus
- Associated Therapies
- -
Pioglitazone in Hepatitis C
- Conditions
- Interventions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2016-12-16
- Lead Sponsor
- University of Michigan
- Target Recruit Count
- 40
- Registration Number
- NCT00189163
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
Efficacy of Pioglitazone on Macrovascular Outcome in Patients With Type 2 Diabetes
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2012-02-28
- Lead Sponsor
- Takeda
- Target Recruit Count
- 4373
- Registration Number
- NCT00174993
Abdominal Adipose Tissue Distribution in Type 2 Diabetic Patients Treated During 6 Months With Pioglitazone or Insulin
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2007-11-08
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 28
- Registration Number
- NCT00159211
- Locations
- 🇫🇷
Sce de Diabétologie, hôpital de la Pitié-salpêtrière, 83bld de l'hôpital, Paris, France
Treatment of Coronary Atherosclerosis by Insulin Sensitizers in Insulin-Resistant Patients
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2006-02-27
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT00155350
- Locations
- 🇨🇳
Division of Cardiology, Department of Internal Medicine and Department of Medical Imaging, National Taiwan University Hospital, Taipei, Taiwan
Effects of Pioglitazone in Congenital Adrenal Hyperplasia
- Conditions
- First Posted Date
- 2005-09-09
- Last Posted Date
- 2007-03-01
- Lead Sponsor
- Radboud University Medical Center
- Registration Number
- NCT00151710
- Locations
- 🇳🇱
Radboud University Nijmegen Medical Centre, Nijmegen, Gelderland, Netherlands
Effect of Pioglitazone on HIV-1 Related Lipoatrophy: a Randomized, Double Blind, Placebo-Controlled Trial in 130 Patients
- Conditions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2005-10-20
- Target Recruit Count
- 130
- Registration Number
- NCT00148850
- Locations
- 🇫🇷
Service des Maladies Infectieuses et Tropicales, Hopital Tenon, Paris, France
Pioglitazone Treatment in Polycystic Ovary Syndrome
- Conditions
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2008-09-26
- Lead Sponsor
- Odense University Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT00145340
- Locations
- 🇩🇰
Department of Endocrinology, Odense University Hospital, Odense, Funen, Denmark
Placebo and Active Controlled Study of Rivoglitazone in Type 2 Diabetes
- Conditions
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2021-05-10
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 441
- Registration Number
- NCT00143520
Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 318
- Registration Number
- NCT00138554
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Study Assessing Saxagliptin Treatment In Type 2 Diabetic Subjects Who Are Not Controlled With Metformin Alone
- Conditions
- Interventions
- First Posted Date
- 2005-07-21
- Last Posted Date
- 2015-04-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1462
- Registration Number
- NCT00121667
- Locations
- 🇨🇳
Local Institution, Taipei, Taiwan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.